HUTCHMED (CHINA) LIMIT

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

16 5 2024 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

13 5 2024 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

13 5 2024 20:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

10 5 2024 09:45:09 提供 NetDania Notify

NetDania - New 12 months High: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

09 5 2024 09:45:13 提供 NetDania Notify

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

08 5 2024 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

26 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

05 4 2024 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

02 4 2024 00:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

27 3 2024 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

21 3 2024 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

28 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

06 2 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

02 2 2024 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Final Results

01 2 2024 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

29 1 2024 23:53:49 提供 Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

10 1 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

12 12 2023 23:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

12 12 2023 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

30 11 2023 19:00:00 提供 Nasdaq GlobeNewswire